You are here

Clinically suitable approach for gene-mediated therapy of cirrhosis.

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AA024000-01
Agency Tracking Number: R43AA024000
Amount: $224,999.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAAA
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
440 Lexington St
AUBURNDALE, MA 02466-1923
United States
DUNS: 192959851
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ESTUARDO AGUILAR-CORDO
 (617) 916-5445
 eaguilar@advantagene.com
Business Contact
 ESTUARDO CORDOVA
Phone: (617) 916-5445
Email: eaguilar@advantagene.com
Research Institution
 Stub
Abstract

Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhosis. While fibrosis is a normal wound healing response, in excess, it can further injure tissue and activate pro-fibrotic cells, resulting in a positive feedback loop. Scar tissue is not static, ECM remodeling is a dynamic and regulated process that holds promise for targeted intervention of fibrotic disease. Furthermore, recent observations suggest the potential for the 'reversal' of advanced liver disease upon removal of the source of injury. In cirrhosis, aggressive removal of scar tissue would likely be needed to halt the positive feedback loop and create space for healthy hepatocyte growth. One hypothesis for achieving this is the introduction of ECM regulating enzymes, such as the collagenase Matrix Metalloprotienase-8 (MMP-8), thus shifting the balance of pro-fibrotic versus anti-fibrotic components, break

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government